The global self-injection devices market is growing at a rapid rate. This is predominantly due to the high growth in development of biological drugs, which have low therapeutic potency, meaning they need to be administered in high doses to be effective, often resulting in viscous formulations.

Many device manufacturers claim to be able to deliver viscous formulations but a great deal of care needs to be taken because they may be achieving this simply by using a rather large needle which can contribute to pain and a poor user experience. However, Bespak by Recipharm has developed a drug delivery device technology to address the challenges faced with viscous formulation.

Find out more from the experts with a strong track record in effective device development